These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26186911)

  • 1. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Bender D; Sill MW; Lankes HA; Reyes HD; Darus CJ; Delmore JE; Rotmensch J; Gray HJ; Mannel RS; Schilder JM; Hunter MI; McCourt CK; Samuelson MI; Leslie KK
    Gynecol Oncol; 2015 Sep; 138(3):507-12. PubMed ID: 26186911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
    Powell MA; Sill MW; Goodfellow PJ; Benbrook DM; Lankes HA; Leslie KK; Jeske Y; Mannel RS; Spillman MA; Lee PS; Hoffman JS; McMeekin DS; Pollock PM
    Gynecol Oncol; 2014 Oct; 135(1):38-43. PubMed ID: 25019571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
    Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
    J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
    Leslie KK; Sill MW; Fischer E; Darcy KM; Mannel RS; Tewari KS; Hanjani P; Wilken JA; Baron AT; Godwin AK; Schilder RJ; Singh M; Maihle NJ
    Gynecol Oncol; 2013 Jun; 129(3):486-94. PubMed ID: 23438670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
    Aghajanian C; Sill MW; Darcy KM; Greer B; McMeekin DS; Rose PG; Rotmensch J; Barnes MN; Hanjani P; Leslie KK
    J Clin Oncol; 2011 Jun; 29(16):2259-65. PubMed ID: 21537039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
    Rimel BJ; Enserro D; Bender DP; Jackson CG; Tan A; Alluri N; Borowsky M; Moroney J; Hendrickson AW; Backes F; Swisher E; Powell M; MacKay H
    Cancer; 2024 Apr; 130(8):1234-1245. PubMed ID: 38127487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
    Chan JK; Deng W; Higgins RV; Tewari KS; Bonebrake AJ; Hicks M; Gaillard S; Ramirez PT; Chafe W; Monk BJ; Aghajanian C
    Gynecol Oncol; 2017 Sep; 146(3):554-559. PubMed ID: 28728751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
    Coleman RL; Sill MW; Thaker PH; Bender DP; Street D; McGuire WP; Johnston CM; Rotmensch J
    Gynecol Oncol; 2015 Jul; 138(1):30-5. PubMed ID: 25887099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
    Campbell NP; Kunnavakkam R; Leighl N; Vincent MD; Gandara DR; Koczywas M; Gitlitz BJ; Agamah E; Thomas SP; Stadler WM; Vokes EE; Kindler HL
    Lung Cancer; 2012 Oct; 78(1):76-80. PubMed ID: 22831987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.
    Makker V; Filiaci VL; Chen LM; Darus CJ; Kendrick JE; Sutton G; Moxley K; Aghajanian C
    Gynecol Oncol; 2015 Jul; 138(1):24-9. PubMed ID: 25888978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
    Leslie KK; Sill MW; Lankes HA; Fischer EG; Godwin AK; Gray H; Schilder RJ; Walker JL; Tewari K; Hanjani P; Abulafia O; Rose PG
    Gynecol Oncol; 2012 Nov; 127(2):345-50. PubMed ID: 22885469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
    Sridhar SS; Mackenzie MJ; Hotte SJ; Mukherjee SD; Tannock IF; Murray N; Kollmannsberger C; Haider MA; Chen EX; Halford R; Wang L; Ivy SP; Moore MJ
    Invest New Drugs; 2013 Aug; 31(4):1008-15. PubMed ID: 23354849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
    Hirte H; Lheureux S; Fleming GF; Sugimoto A; Morgan R; Biagi J; Wang L; McGill S; Ivy SP; Oza AM
    Gynecol Oncol; 2015 Jul; 138(1):55-61. PubMed ID: 25895616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
    Matulonis UA; Berlin S; Ivy P; Tyburski K; Krasner C; Zarwan C; Berkenblit A; Campos S; Horowitz N; Cannistra SA; Lee H; Lee J; Roche M; Hill M; Whalen C; Sullivan L; Tran C; Humphreys BD; Penson RT
    J Clin Oncol; 2009 Nov; 27(33):5601-6. PubMed ID: 19826113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
    Alvarez EA; Brady WE; Walker JL; Rotmensch J; Zhou XC; Kendrick JE; Yamada SD; Schilder JM; Cohn DE; Harrison CR; Moore KN; Aghajanian C
    Gynecol Oncol; 2013 Apr; 129(1):22-7. PubMed ID: 23262204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
    Matei D; Sill MW; Lankes HA; DeGeest K; Bristow RE; Mutch D; Yamada SD; Cohn D; Calvert V; Farley J; Petricoin EF; Birrer MJ
    J Clin Oncol; 2011 Jan; 29(1):69-75. PubMed ID: 21098323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
    Coleman RL; Sill MW; Lankes HA; Fader AN; Finkler NJ; Hoffman JS; Rose PG; Sutton GP; Drescher CW; McMeekin DS; Hu W; Deavers M; Godwin AK; Alpaugh RK; Sood AK
    Gynecol Oncol; 2012 Dec; 127(3):538-43. PubMed ID: 22922531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
    Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman S
    Neuro Oncol; 2015 Oct; 17(10):1386-92. PubMed ID: 26008604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
    Brown N; McBain C; Nash S; Hopkins K; Sanghera P; Saran F; Phillips M; Dungey F; Clifton-Hadley L; Wanek K; Krell D; Jeffries S; Khan I; Smith P; Mulholland P
    PLoS One; 2016; 11(5):e0156369. PubMed ID: 27232884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
    Dizon DS; Sill MW; Schilder JM; McGonigle KF; Rahman Z; Miller DS; Mutch DG; Leslie KK
    Gynecol Oncol; 2014 Dec; 135(3):441-5. PubMed ID: 25312396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.